Federation de Biologie

Clamart, France

Federation de Biologie

Clamart, France
SEARCH FILTERS
Time filter
Source Type

Garcia Hejl C.,Federation de Biologie | Riviere F.,Pneumologie | Sanmartin N.,Federation de Biologie | Fabre M.,Federation de Biologie | And 2 more authors.
Medecine et Sante Tropicales | Year: 2015

We report a case of Mycobacterium simiae pneumonia in an immunocompetent women aged 55 years, after a stay in Thailand. The diagnosis was based on culture isolation of non-tuberculous mycobacteria from bronchoalveolar lavage. The culture isolate was identified as M. simiae by biochemical and molecular methods. The patient was treated. Her condition remained stable for 5 years. During the sixth years, a relapse occurred, and a new treatment was prescribed. This is a rare case in view of the absence of any predisposing factor. M. simiae should be conside- red a possible causative agent of pulmonary disease, even in immunocompetent patients. © 2015, John Libbey Eurotext. All rights reserved.


PubMed | Federation de Biologie and Pneumologie
Type: Case Reports | Journal: Medecine et sante tropicales | Year: 2015

We report a case of Mycobacterium simiae pneumonia in an immunocompetent women aged 55 years, after a stay in Thailand. The diagnosis was based on culture isolation of non-tuberculous mycobacteria from bronchoalveolar lavage. The culture isolate was identified as M.simiae by biochemical and molecular methods. The patient was treated. Her condition remained stable for 5 years. During the sixth years, a relapse occurred, and a new treatment was prescribed. This is a rare case in view of the absence of any predisposing factor. M.simiae should be considered a possible causative agent of pulmonary disease, even in immunocompetent patients.


Solas C.,Laboratoire Of Pharmacocinetique Et Toxicologie | Gagnieu M.-C.,Federation de Biologie
Therapie | Year: 2011

The efavirenz, a non nucleoside reverse transcriptase inhibitor of HIV-1, presents a marked pharmacokinetics variability related to an intense hepatic metabolism. Efavirenz is also a potent inducer. Central nervous system (CNS) toxicity associated with efavirenz therapy is a major cause of non adherence and therefore treatment failure. The literature has been analyzed to evaluate the level of evidence of the interest of a therapeutic drug monitoring for efavirenz. Several studies have reported that an efavirenz plasma concentration >1000 ng/mL is a predictive factor of the viral response. Efavirenz plasma concentrations >4000 ng/mL were associated to an increase frequency of CNS side effects. CNS toxicity was also more frequent in patients carrying the 516G > T mutation (CYP2B6*6 allele), associated with a significantly greater efavirenz plasma exposure. Non-randomized studies have reported the interest of efavirenz therapeutic drug monitoring to optimize viral response and prevent CNS toxicity, allowing to suggest a level of evidence "recommended" for efavirenz. © 2011 Société Française de Pharmacologie et de Thérapeutique.


Desideri-Vaillant C.,Federation de biologie | Galinat H.,Federation de biologie | Sapin-Lory J.,Federation de biologie | Valero E.,Federation de biologie | And 2 more authors.
Transfusion Clinique et Biologique | Year: 2011

This report is devoted to the soluble transferrin receptors. We analyzed the comparison between ferritin, soluble transferrin receptors and C reactive protein. The soluble receptor measurement represents a significal advance in assessment of iron status, especially in the diagnosis of iron deficiency associated with inflammation, and in the evaluation of red blood mass during erythroid hyperplasias. © 2011 Elsevier Masson SAS.

Loading Federation de Biologie collaborators
Loading Federation de Biologie collaborators